News – Page 1035 – Endpoints News

Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study

8 years ago

Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

8 years ago

Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai

8 years ago

IPO plans brewing, Innovent Biologics raises $150M and eyes hundreds of millions more

8 years ago

Ex-AstraZeneca exec Lisa Anson to lead do-over at Redx; Advaxis shakes up C-suite

8 years ago

Two more top FDA officials hit the exits as an exodus of senior regulators continues

8 years ago

Vertex's rapid-fire PhIII program hits a roadblock at the FDA. Will regulators force rival Galapagos to slow down ...

8 years ago

Alexion preps an FDA pitch on Soliris successor while signaling more deals ahead for rare disease drugs

8 years ago

CRISPR legend Jennifer Doudna helps some recent college grads launch a diagnostics upstart

8 years ago

Senti scientific co-founder Wilson Wong designs the SUPRA — a new, high performance model CAR-T

8 years ago

Achaogen earns $12M award for next-gen antibiotics; Endo acquires Somerset for $190M

8 years ago

GSK tips its hat on new deals, reviews incentives as Hal Barron cooks up a turnaround plan for its lackluster R&D ...

8 years ago

Amid hot IPO season, Mereo drops Nasdaq plans citing 'challenging' market conditions

8 years ago

Celgene's disclosures about ozanimod this week spur analysts' fears of a lengthy delay for a key drug

8 years ago

Roche flags first case of anti-drug antibodies that forced a patient to drop would-be blockbuster Hemlibra

8 years ago

Forget Nasdaq. China’s biotechs with blockbuster IPO dreams are switching focus to Hong Kong

8 years ago

Acadia shares slide — again — after FDA confirms it has launched a safety review of Nuplazid

8 years ago

Venrock-backed startup Corvidia snags $60M round to develop ex-AstraZeneca drug

8 years ago

AbbVie advances its two star pipeline therapies, filing BLA for risankizumab and posting promising data for ...

8 years ago

After mega-round investment, ADC Therapeutics cans PhI trial in HER2

8 years ago

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

8 years ago

After decades in the big leagues, Martin Mackay is going small — and he's delighted

8 years ago

Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff

8 years ago

'Site-less' trials in mind, Novartis launches an app for ophthalmology research

8 years ago

First page Previous page 1032 1033 103410351036 1037 1038 Next page Last page